{
    "nctId": "NCT00408863",
    "briefTitle": "Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)",
    "officialTitle": "A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Investigate Safety and Efficacy of Tibolone (Org OD14) in Women With Climacteric Symptoms and a History of Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Climacteric Symptoms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 3148,
    "primaryOutcomeMeasure": "To show non-inferiority in breast cancer recurrence of tibolone 2.5 mg versus placebo in women with climacteric symptoms who have been surgically treated for primary breast cancer within the last 5 years",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed and surgically treated invasive breast carcinoma (T1/2/3 N0/1/2 M0), irrespective of hormonal (estrogen/progestogen) receptor status.\n* Last menstrual bleeding at least 12 months before the start of the study or ovariectomized or hysterectomized or currently being treated with gonadotropin releasing hormone analogs.\n* Vasomotor symptoms whether related to natural menopause, ovariectomy, or to breast cancer therapy (chemotherapy, tamoxifen, aromatase inhibitors or other anticancer therapy).\n* In subjects with an intact uterus, a 'normal' endometrium, defined as:\n\n  1. in tamoxifen users: absence of endometrial polyps\n  2. in non-tamoxifen users: double layer endometrial thickness \\<=4 mm as assessed by TVUS or double layer endometrial thickness \\>4 mm and \\<=8 mm as assessed by TVUS plus an endometrial biopsy result of inactive/atrophic.\n* Voluntary written informed consent and willing and able to make reasonable efforts to meet all clinical trial requirements.\n\nExclusion Criteria:\n\n* Age \\>75 years at baseline.\n* Ductal carcinoma in situ (DCIS) of the breast without the existence of invasive breast carcinoma.\n* Invasive breast carcinoma having a tumor of any size with direct extension to chest wall or skin (T4) and/or having metastasis to ipsilateral mammary lymph node(s) (N3) and/or having presence of distant metastasis (M1).\n* Surgical treatment of the primary breast cancer \\>5 years ago.\n* History or presence of residual or recurrent breast cancer.\n* History or presence of endometrial cancer.\n* History or presence of any other malignancy (besides breast cancer and endometrial cancer) within the past 5 years, except for adequately treated basal cell carcinoma of the skin.\n* Diagnostic findings suspicious for any malignancy.\n* Double layer endometrial thickness \\>8 mm as assessed by TVUS in subjects not being treated with tamoxifen.\n* Final diagnosis of endometrial biopsy different from inactive/atrophic\n* Existence of endometrial polyps as demonstrated by TVUS.\n* Undiagnosed vaginal bleeding.\n* Abnormal cervical smear (corresponding to PAP IIb or higher)\n* Any previous or current unopposed estrogen administration in women with an intact uterus (occasional use of estrogen-containing vaginal cream was allowed after an appropriate washout period - see below).\n* Use of systemic estrogens and/or progestogens (including intra-uterine progestogen therapy) and/or tibolone and/or phytoestrogens within 8 weeks prior to baseline; use of transdermal hormone therapy and/or local estrogen applications and/or non-hormonal medication for vasomotor symptoms within 4 weeks prior to baseline.\n* Use of progestogen implants or injections and/or estrogen/progestogen injectable therapy within the past 6 months.\n* Use of estrogen implants or injections within the past 5 years.\n* Use of raloxifene hydrochloride and/or any non-registered investigational drug within the last 8 weeks.\n* Active deep vein thrombosis, thromboembolic disorders, or a documented history of these conditions.\n* Severe liver disorders.\n* Abnormal laboratory values considered to be clinically relevant by the investigator.\n* Any disease or condition that is clinically relevant and which, in the opinion of the investigator, would jeopardize the subject's well-being during the course of the trial.\n* Known hypersensitivity to tibolone or any of its components\n* Known or suspected pregnancy\n* Age \\<40 years at baseline and planned breast cancer therapy \\<2 years after baseline",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}